BRIGHT MINDS BIOSCIENCES

Bright Minds Biosciences placed 1,945,000 common shares at $90.00 each, generating gross proceeds of $175.05 million. The syndicate banks were granted a 30-day overallotment option for up to 291,750 additional shares. The funds are intended to finance clinical trials (including the start of phase 1 for BMB-105), research and development of earlier programs, and general corporate purposes. » Más en de.investing.com

Bright Minds Biosciences has set the price for a public offering of 1,945,000 common shares at $90.00 per share and expects gross proceeds of about $175.05 million. The underwriters were granted a 30-day option to purchase up to 291,750 additional shares at the same price; closing is expected on January 9, 2026. The proceeds are intended to fund clinical trials for several drug candidates; the company has simultaneously ended its at-the-market program. Analysts mostly rate the stock as "Buy," and the share price and market capitalization have risen sharply after a strong rally. » Más en de.investing.com

Bright Minds Biosciences announced a public offering of common stock and pre-funded warrants totaling $100 million and granted the underwriters a 30-day option to purchase up to 15% of the offered common stock. Proceeds are intended to fund clinical trials for drugs targeting absence seizures, DEE and Prader‑Willi syndrome, as well as Phase 1 studies for BMB‑105, earlier-stage research and general corporate purposes. The offering is being made under an F-3 registration; Jefferies, TD Cowen, Piper Sandler and Cantor are serving as joint book-running managers. The company reports a strong balance sheet with more cash than debt and a current ratio of 36.1. » Más en de.investing.com